Innapharma

Innapharma was a U.S. biopharmaceutical company focused on discovering and developing proprietary peptide therapeutics for serious diseases, with a primary emphasis on central nervous system disorders. The company is best known for its small chain peptide platform and its lead antidepressant candidate, Nemifitide (INN 00835), which was developed for major depressive disorder. Historical sources indicate that Innapharma filed for Chapter 11 bankruptcy in 2003 and later merged into Tetragenex Pharmaceuticals, which emerged from bankruptcy in 2004. As a result, Innapharma appears to be a historical company name rather than an active standalone operating biotech today. The available record suggests a legacy development-stage CNS biotech rather than a currently operating commercial pharma company.